

Running head: MicroRNA expression in high and low capacity runner rats

1 Running Head: MicroRNA regulation in high and low running capacity rats

2

3 Expression of microRNAs and target proteins in skeletal muscle of rats selectively bred for  
4 high and low running capacity

5

6 Samuel K. Pinto<sup>1</sup>, Séverine Lamon<sup>2</sup>, Erin J. Stephenson<sup>3</sup>, Ming Kalanon<sup>2</sup>, Jasmine Mikovic<sup>2</sup>,  
7 Lauren G. Koch<sup>4</sup>, Steven L. Britton<sup>4</sup>, John A. Hawley<sup>1,5</sup>, Donny M. Camera<sup>1</sup>

8

9 <sup>1</sup>Centre for Exercise and Nutrition, Mary MacKillop Institute for Health Research, Australian  
10 Catholic University, Melbourne, Victoria, Australia; <sup>2</sup>Institute for Physical Activity and  
11 Nutrition, School of Exercise and Nutrition Sciences, Deakin University Geelong, Victoria,  
12 Australia; <sup>3</sup>Department of Physiology, University of Tennessee Health Science Center,  
13 Memphis, Tennessee; Department of Pediatrics, University of Tennessee Health Science  
14 Center, Memphis, Tennessee; and Children's Foundation Research Institute, Le Bonheur  
15 Children's Hospital, Memphis, Tennessee; <sup>4</sup>Department of Anaesthesiology, University of  
16 Michigan, Ann Arbor, Michigan, USA; <sup>5</sup>Research Institute for Sport and Exercise Sciences,  
17 Liverpool John Moores University, Liverpool, United Kingdom

18

19 Author for correspondence:

20 Donny Camera

21 Centre for Exercise and Nutrition; Mary MacKillop Institute for Health Research

22 Australian Catholic University

23 Level 5, 215 Spring St, Melbourne VIC 3000; Australia

24 Email: donny.camera@acu.edu.au

25 Phone: +61 9953 3527

26 **Abstract**

27 Impairments in mitochondrial function and substrate metabolism are implicated in the  
28 etiology of obesity and type 2 diabetes. MicroRNAs (miRNAs) can degrade mRNA or  
29 repress protein translation and have been implicated in the development of such disorders.  
30 We used a contrasting rat model system of selectively bred high- (HCR) or low- (LCR)  
31 intrinsic running capacity with established differences in metabolic health to investigate the  
32 molecular mechanisms through which miRNAs regulate target proteins mediating  
33 mitochondrial function and substrate oxidation processes. Quantification of select miRNAs  
34 using the Rat miFinder miRNA PCR array revealed differential expression of 15 skeletal  
35 muscle (*m. tibialis anterior*) miRNAs between HCR and LCR rats (14 with higher expression  
36 in LCR;  $P < 0.05$ ). Ingenuity Pathway Analysis predicted these altered miRNAs to collectively  
37 target multiple proteins implicated in mitochondrial dysfunction and energy substrate  
38 metabolism. Total protein abundance of citrate synthase (CS; miR-19 target) and voltage-  
39 dependent anion channel 1 (miR-7a target) were higher in HCR compared to LCR cohorts  
40 (~57 and ~26%, respectively;  $P < 0.05$ ). A negative correlation was observed for miR-19a-3p  
41 and CS ( $r = 0.59$ ,  $P = 0.02$ ) protein expression in LCR. To determine if miR-19a-3p can  
42 regulate CS *in vitro* we performed luciferase reporter and transfection assays in C2C12  
43 myotubes. MiR-19a-3p binding to the CS untranslated region did not change luciferase  
44 reporter activity, however miR-19a-3p transfection decreased CS protein expression (~70%;  
45  $P < 0.05$ ). The differential miRNA expression targeting proteins implicated in mitochondrial  
46 dysfunction and energy substrate metabolism may contribute to the molecular basis  
47 mediating the divergent metabolic health profiles of LCR and HCR rats.

48

49

50 Key words: Mitochondrial dysfunction, substrate oxidation, gene expression, citrate synthase

51 **Introduction**

52 Metabolic disorders such as type 2 diabetes and obesity are characterized by a loss of  
53 ‘metabolic plasticity’ where skeletal muscle is unable to effectively transition between lipid-  
54 and carbohydrate-based oxidation in response to the prevailing hormonal milieu (17).  
55 Development of these clinical conditions is determined by a complex interaction of  
56 environmental (lifestyle) and genetic (heritable) factors. Through two-way artificial selection  
57 breeding for treadmill running capacity, intrinsically high capacity runner (HCR) and low  
58 capacity runner (LCR) rats provide an excellent model system for studying the genetic factors  
59 mediating extremes in metabolic health. The HCR rats present with over 8-fold greater  
60 intrinsic aerobic running capacity at generation 28 compared to LCR rats and over 40% of the  
61 variance of the running capacity phenotype due to additive genetic variance (narrow-sense  
62 heritability,  $h^2 = 0.47 \pm 0.02$  in HCRs and  $0.43 \pm 0.03$  in LCRs) (31). This superior aerobic  
63 capacity and metabolic health profile of HCR rats has, in part, been attributed to an increased  
64 activity of skeletal muscle proteins involved in mitochondrial function and substrate  
65 oxidation (15, 29, 33, 38) compared to the impaired mitochondrial function observed in LCR  
66 animals (34, 38). Thus, investigating the gene-regulatory mechanisms mediating these  
67 processes in a translational animal model system may provide new insight to the molecular  
68 basis controlling metabolic health.

69

70 MicroRNAs (miRNAs) are short, non-coding RNAs that regulate gene expression by binding  
71 to mRNA, subsequently instigating degradation or repressing protein translation (2, 10).  
72 Altered miRNA expression has been implicated in the pathogenesis of several metabolic  
73 conditions including obesity and type 2 diabetes through the regulation of key metabolic  
74 signaling networks involved in glucose and lipid handling, and mitochondrial metabolism (9,  
75 13, 43). Additionally, divergent miRNA expression has recently been characterized in mice

76 with inherently high or low physical activity levels as well in human ‘high’ and ‘low’  
77 responders to resistance exercise (5, 6). These findings suggest that miRNAs may contribute  
78 to the metabolic adaptation profile induced by physical/exercise activity. Whether miRNAs  
79 contribute to the signaling pathways that mediate the intrinsic skeletal muscle metabolic  
80 phenotypes divergent between HCR and LCR rats is unknown. We aimed to determine the  
81 miRNA expression profile and interactions with predicted protein targets implicated in  
82 metabolic health in skeletal muscle from HCR and LCR rats. We hypothesized that HCR and  
83 LCR rats would present divergent miRNA expression profiles in a non-exercise condition,  
84 with HCR rats displaying a miRNA profile that upregulates proteins promoting efficient  
85 substrate oxidation and enhanced mitochondrial function.

86

## 87 **Materials and Methods**

### 88 *Experimental animals*

89 HCR and LCR rats derived from genetically heterogeneous N:NIH stock rats by two-way  
90 artificial selection for maximal treadmill running capacity were used in this study. The  
91 breeding program and aerobic capacity testing procedures have been described in detail  
92 previously (20). Parent rats from generation 27 of selection were bred at the University of  
93 Michigan (Ann Arbor, MI, USA) and their female offspring, HCR (n = 12) and LCR (n =  
94 12), transported to Royal Melbourne Institute of Technology (RMIT) University (Bundoora,  
95 Australia) at ~8 weeks (wk) of age. We have previously reported maximal respiratory  
96 capacity and fasting serum insulin concentrations from this LCR/ HCR generation (REF).  
97 HCRs from later generations (i.e.: 23-27) have shown similar increases in running capacity  
98 and Citrate Synthase activity above LCRs compared to earlier generations (7-11) (16, 34, 39,  
99 41). Rats were allowed 2 wk to acclimate to RMIT facilities as previously described (38).  
100 Neither HCR or LCR rats underwent any form of exercise training during the study period.

101 Rats received ad libitum access to water and a standard chow diet whilst being housed under  
102 a 12:12 hour light-dark cycle in a temperature controlled environment (22 °C). Experimental  
103 procedures were approved by the University Committee on Use and Care of Animals at the  
104 University of Michigan and the RMIT University Animal Ethics Committee prior to the onset  
105 of the study.

106

#### 107 *Tissue collection*

108 At 11 wk of age, rats were weighed and anesthetized using pentobarbital sodium (60 mg/kg  
109 body wt). The *m. tibialis anterior* (TA) was immediately excised, freeze clamped in liquid  
110 nitrogen and stored at -80 °C for subsequent analysis.

111

#### 112 *RNA extraction and quantification*

113 RNA extraction from skeletal muscle tissue was performed using TRIzol in accordance with  
114 the manufacturer's instructions and described previously (3). Briefly, approximately 20 mg of  
115 tissue was homogenized in TRIzol and chloroform was added to form an aqueous upper  
116 phase which was precipitated by adding isopropanol. The remaining RNA pellet was washed  
117 and re-suspended in 35 µL's RNase-free water. RNA was quantified using a NanoDrop 2000  
118 Spectrophotometer (Thermo Fisher Scientific, MA, USA).

119

#### 120 *Reverse Transcription (RT) and Real-Time PCR*

121 A miScript II RT Kit (catalogue #218160; Qiagen, Melbourne, Australia) was used to  
122 synthesize cDNA from RNA samples using a BioRad thermal cycler (BioRad Laboratories,  
123 Gladesville, Australia) in accordance with the manufacturer's instructions. Changes in  
124 miRNA expression were quantified using a Rat miFinder miRNA PCR Array (catalogue  
125 #MIRN-001ZD-24; Qiagen, Melbourne, Australia) in a 96-well RT cycler CFX96 (BioRad

126 Laboratories, Gladesville, Australia) for 40 cycles (two steps: 95°C for 15 s followed by 60°C  
127 for 30 s). This microarray contained the 84 most abundantly expressed and best characterized  
128 miRNAs present in rats. These miRNA targets can be found via the link:  
129 [http://www.sabiosciences.com/mirna\\_pcr\\_product/HTML/MIRN-001Z.html](http://www.sabiosciences.com/mirna_pcr_product/HTML/MIRN-001Z.html) This microarray  
130 was selected as many of these miRNAs have been previously shown to regulate targets  
131 shown to have roles in substrate oxidation and mitochondrial function (4, 8, 11, 27) and is  
132 therefore relevant to the HCR and LCR experimental model. Six housekeeping control RNAs  
133 were also measured on this microarray for normalization. The relative amounts of each  
134 miRNA in PCR analysis was normalised to the average of these six (SNORD61, SNORD68,  
135 SNORD72, SNORD95, SNORD96A, RNU6-2) house-keeping genes. There were no  
136 changes in the absolute CT of each individual house-keeping gene or the average between  
137 LCR and HCR cohorts (data not shown). The  $2^{\Delta\Delta CT}$  method of relative quantification was  
138 used to calculate relative amounts of miRNAs (28).

139

#### 140 *miRNA target prediction*

141 Protein/mRNA targets of miRNAs differentially expressed ( $P < 0.05$ ) between HCR and LCR  
142 skeletal muscle were predicted using the microRNA Target Filter function of Qiagen's  
143 Ingenuity Pathway Analysis (IPA, QIAGEN Redwood City, [www.qiagen.com/ingenuity](http://www.qiagen.com/ingenuity)).  
144 IPA's microRNA Target Filter incorporates multiple target prediction programs including  
145 TargetScan, TarBase, miRecords and the Ingenuity Knowledge Base. Predicted relationships  
146 were filtered to be either 'highly predicted' by algorithms or 'experimentally observed' by  
147 previous research. Predicted targets were then filtered to be implicated in 'Mitochondrial  
148 Dysfunction' and 'TCA Cycle II (Eukaryotic)' in skeletal muscle. These filter criteria were  
149 selected for investigation as LCR rats exhibit impaired skeletal muscle mitochondrial and  
150 TCA cycle function compared to HCR (34, 38). Predicted targets meeting these criteria were

151 identified for 11 of the 15 miRNAs differentially expressed between HCR and LCR rats. A  
152 minimum of one predicted protein/mRNA target was selected for further protein expression  
153 analysis (described subsequently) for each of the 11 differentially expressed miRNAs which  
154 presented protein/mRNA targets implicated in ‘Mitochondrial Dysfunction’ and ‘TCA cycle  
155 II (Eukaryotic)’.

156

157 *Western Blotting (skeletal muscle)*

158 Approximately 30 mg of TA was homogenized in ice-cold buffer as previously described  
159 (39). Lysates were centrifuged at 12,000 g for 20 min at 4 °C and the supernatant was  
160 transferred to a sterile microcentrifuge tube and aliquoted to measure protein concentration  
161 using a bicinchoninic acid protein assay (Pierce, Rockford, IL, USA). Lysate was then re-  
162 suspended in 4X Laemmli sample buffer with 40 µg of protein loaded onto 4–20% Mini-  
163 PROTEAN TGX Stain-Free™ Gels (BioRad Laboratories, Gladesville, Australia). Post  
164 electrophoresis, gels were activated on a Chemidoc according to the manufacturer’s  
165 instructions (BioRad Laboratories, Gladesville, Australia) and then transferred to  
166 polyvinylidene fluoride (PVDF) membranes. After transfer, a stain-free image of the PVDF  
167 membranes (14) for total protein normalization was obtained before membranes were rinsed  
168 briefly in distilled water and blocked with 5% non-fat milk, washed with 10 mM of Tris–  
169 HCl, 100 mM of NaCl, and 0.02% Tween 20, and incubated with primary antibody (1:1000)  
170 overnight at 4 °C. Membranes were then incubated with secondary antibody (1:2000), and  
171 proteins were detected via enhanced chemiluminescence (Thermo Fisher, Scoresby,  
172 Australia) and quantified by densitometry (ChemiDoc™ XRS+ System; BioRad  
173 Laboratories, California, USA). HCR and LCR samples were run on the same gel. Primary  
174 antibodies used were polyclonal caspase-3 (CASP3) (#9662), leucine-rich repeat kinase 2  
175 (LRRK2) (#5559) (Cell Signaling, Beverly, MA, USA), polyclonal ATP synthase

176 mitochondrial F1 complex assembly factor 1 (ATPAF1) (#ab101518), beta-site APP cleaving  
177 enzyme 1 (BACE1) (#ab2077), Citrate Synthase (CS) (ab96600) and monoclonal Glycerol-3-  
178 Phosphate Dehydrogenase 2 (GPD2) (ab188585), MAP2K4 (ab33912), VDAC1 (ab14734)  
179 (Abcam, Cambridge, UK). Volume density of each target protein band was normalized to the  
180 total protein loaded into each lane using stain-free technology (14), with data expressed in  
181 arbitrary units (Figure 7).

182

### 183 *Citrate synthase activity*

184 CS activity was measured to identify whether differences in CS protein abundance were also  
185 accompanied by differences in activity. Skeletal muscle homogenates ( $n = 10$ ) from freeze  
186 clamped TA muscles (10-20 mg) were prepared over ice in buffer [175 mM KCl and 2 mM  
187 EDTA (pH 7.4), 1:50 or 1:100 dilution]. Homogenates underwent three freeze-thaw cycles  
188 and CS activity was measured according to the method of Srere (37) with modifications as  
189 described previously (38).

190

### 191 *Cell Culture*

192 Stock C2C12 (mouse) myoblasts (ATCC, Manassas, VA, USA) were maintained at 37°C  
193 (95% O<sub>2</sub>-5% CO<sub>2</sub>) in high glucose (4.5g/L D-Glucose) culture medium with 2mM glutamine  
194 and 110 mg/L sodium pyruvate (Dulbecco's modified Eagle's medium (DMEM)), containing  
195 10% fetal bovine serum (FBS; Life Technologies, Melbourne, Australia). For differentiation  
196 experiments, when cultures approached confluence (~90% confluent), medium was changed  
197 to differentiation medium (DMEM, supplemented with 2% horse serum; Life Technologies,  
198 Melbourne, Australia). Differentiation medium was replaced every 24 h.

199

### 200 *Luciferase Reporter Assay*



201 C2C12 myoblasts ( $1-2 \times 10^5$ /mL) were seeded in black-walled 96-well plates. Twenty-four  
202 hours after seeding, cells were co-transfected with 150 ng pNanoglo2 vector (Promega,  
203 Alexandria, Australia) containing either: no insertion (empty control); the putative rat miR-  
204 19a-3p Citrate Synthase target site (including the predicted seed site with 10 base pairs on  
205 either side; Primer sequence- Forward: 5'  
206 CAGCAGCCTCAAttgcacagattttcaGTGACTCAGAccgcggG 3', Reverse: 5'  
207 CTAGCccgcggTCTGAGTCACtgaaaatctgtgcaaaTGAGGCTGCTGAGCT); or its mutant  
208 control, cloned between SacI and NheI downstream of the Nanoluc luciferase (Primer  
209 sequence- Forward 5' CAGCAGCCTCAcaaccaatcgagaactGTGACTCAGAccgcggG 3',  
210 Reverse: 5' CTAGCccgcggTCTGAGTCACagtctcgattggttgTGAGGCTGCTGAGCT 3';  
211 together with 5 nM miR-19a-3p mimics (mirVana™ miRNA mimic, Life technologies,  
212 Mulgrave, Australia), or an irrelevant miRNA control (miR-99b-5p), using Lipofectamine  
213 2000 (Thermo Fisher, Scoresby, Australia) following the manufacturer's protocol. Four  
214 hours' post-transfection, the media was removed and replaced with culture medium. Twenty-  
215 four hours later, cells were assayed for Firefly and Nanoluc luciferase expression using the  
216 Nano-Glo® Dual-luciferase® Reporter assay kit (Promega, Alexandria, Australia) following  
217 the manufacturer's protocol. The data reported are the results of three independent  
218 experiments performed in six replicates.

219

#### 220 *MiRNA transfection*

221 C2C12 myoblasts were cultured (as above) and seeded ( $1.5 \times 10^5$  cells per well) into six-well  
222 plates 24 h before transfection. Myoblasts were transiently transfected with 1nM of miR-19a-  
223 3p mimic and a scramble negative control (mirVana™miRNA mimic, Life technologies)  
224 using Lipofectamine 2000 (Thermo Fisher; Scoresby, Australia). The myoblasts were placed  
225 in transfection medium for 4 h. Following this period, the transfection medium was switched

226 to culture medium until their harvest. RNA and protein were extracted for RT-PCR gene  
227 expression and Western Blot analysis, respectively.

228

229 *Real Time Quantitative PCR and Western Blotting*

230 C2C12 cells were homogenised in TRIZOL and RNA extracted using an RNeasy Mini Kit  
231 (Qiagen, Chadstone, Australia) according to the manufacturer's directions. First-strand cDNA  
232 synthesis was performed using either the SuperScript® VILO™ cDNA Synthesis kit  
233 (Thermo Fisher, Scoresby, Australia) or TaqMan® MicroRNA Reverse Transcription Kit in a  
234 final reaction volume of 20 µl according to the manufacturer's directions. Quantification of  
235 mRNA (in duplicate) was performed on a BioRad CFX96 thermal cycler (BioRad,  
236 Gladesville, Australia). Taqman-FAM-labelled primer/probes for citrate synthase (Cat No.  
237 Mm00466043\_m1) and miR-19a-3p (Cat No. 000395) were used in a final reaction volume  
238 of 20 µl. PCR conditions were 2 min at 50 °C for UNG activation, 10 min at 95 °C then 40  
239 cycles of 95 °C for 15 s and 60 °C for 60 s. β-actin (Cat No. Mm02619580\_g1) and  
240 SnoRNA202 (Cat No. 001232) were used as a housekeeping gene to normalize threshold  
241 cycle (CT) values for mRNA and miRNA analyses, respectively. The relative amounts of  
242 mRNAs were calculated using the relative quantification ( $\Delta\Delta CT$ ) method (28).

243

244 For Western Blot analyses, proteins were lysed in a 1 × modified RIPA (Merck Millipore,  
245 North Ryde, Australia) containing 1:1000 protease inhibitor cocktail (Sigma-Aldrich, Castle  
246 Hill, Australia) and 1:100 Halt phosphatase inhibitor cocktail (Thermo Fisher, Scoresby,  
247 Australia) and left on ice for 30 min prior to centrifugation to remove insoluble material.  
248 Lysates containing twenty micrograms of protein were electrophoresed and transferred as  
249 described above with a stain-free image of the PVDF membranes obtained for total protein  
250 normalization. Transfected and scrambled samples from the same time point of collection

251 were run on the same gel, and the same polyclonal CS antibody as mentioned above was used  
252 to measure CS protein expression. Volume density of each target protein band was  
253 normalized to the total protein loaded into each lane using stain-free technology (10), with  
254 data expressed in arbitrary units (Figure 7).

255

### 256 *Statistical analyses*

257 A two-tailed unpaired t-test (GraphPad Prism Version 5.03) was used to detect differences  
258 between HCR and LCR groups in miRNA expression, protein abundance, enzyme activity  
259 and for all *in vitro* analyses of C2C12 cells. All data was subjected to the normality test using  
260 the Shapiro-Wilk test (SigmaPlot 12.0). Linear regression analysis was performed to  
261 determine associations between miRNA species and their predicted protein targets in HCR  
262 and LCR phenotypes (GraphPad Prism Version 5.03). All values are expressed as arbitrary  
263 units (AU) and presented as mean  $\pm$  standard deviation (SD). Statistical significance was set  
264 at  $P < 0.05$ .

265

## 266 **Results**

### 267 *Differential miRNA expression*

268 There was a higher expression in LCR compared to HCR for let-7i-5p (~147% percent  
269 change), -7e-5p (~93%), miR-7a-5p (~35%), -19a-3p (~66%), -24-3p (~37%), -26a-5p  
270 (~58%), -28-5p (~54%), -30a-5p (~67%), -99a-5p (~54%), -181a-5p (~81%), -194-5p  
271 (~39%), -223-3p (~59%), -374-5p (~68%) and -376c-3p (~121%), while miR-103-3p was  
272 more highly expressed ( $P < 0.05$ ) in HCR than LCR (~31%; Figure 1). All differentially  
273 expressed miRNAs had a mean Ct value  $< 32$ . The other 69 miRNAs analyzed were not  
274 significantly different between HCR and LCR rats (Table 1).

275

276 *Bioinformatics analysis of differentially expressed miRNAs*

277 The microRNA Target Filter function of Qiagen's IPA predicted 5672 mRNAs (2964 in  
278 skeletal muscle) to be targeted by the 15 miRNAs differentially expressed between HCR and  
279 LCR skeletal muscle samples. Eleven of the 15 differentially expressed miRNAs were  
280 predicted to target 19 mRNAs implicated in skeletal muscle mitochondrial dysfunction and  
281 TCA cycle function (Figure 2).

282

283 *Protein abundance of miRNA targets*

284 There was a greater protein abundance of CS (~57%) and VDAC1 (~26%) in HCR compared  
285 to LCR rats ( $P < 0.05$ ; Figure 3A, B). Levels of GPD2 (~28%) were higher in LCR rats ( $P <$   
286  $0.05$ ; Figure 3C). There were no changes in the expression of CASP3, LRRK2, ATPAF1,  
287 BACE1, or MAP2K4 between HCR and LCR rats (Figure 3).

288

289 *miRNA-protein correlations*

290 A significant negative correlation was observed for miR-19a-3p and CS expression in LCR  
291 rats ( $r = 0.59$ ,  $P = 0.02$ ; Figure 4) compared to the HCR ( $r = XX$ ,  $P = 0.76$ , data not shown).  
292 No other correlations between miRNAs and target proteins were found.

293

294 *Citrate Synthase Activity*

295 CS activity was significantly greater in HCR relative to LCR rats (~58%;  $P < 0.05$ , Figure 5).

296

297 *Luciferase reporter assay and miR-19a-3p transfection*

298 There were no changes in Nanoluc luciferase activity in cells co-transfected with the miR-  
299 19a-3p mimic and either the full length CS 3'UTR or the predicted miR\_19a-3p target site on  
300 CS 3'UTR compared to cells transfected with an irrelevant miRNA (data not shown).

301 Transfection of miRNA mimics significantly increased levels of miR-19a-3p expression by  
302 ~8,165 % following 4 h transfection (Figure 6A). Citrate synthase mRNA levels were  
303 unchanged following miR-19a-3p transfection (Figure 6B) however there was a ~70%  
304 reduction in CS protein abundance compared to the scrambled negative control 4 h  
305 transfection (Figure 6C).

306

## 307 **Discussion**

308 MicroRNAs have emerged as key regulators of metabolic health through their ability to  
309 repress gene and protein expression (2) and may mediate underlying differences in intrinsic  
310 metabolic function between individuals. Using an animal model of inherited low- or high  
311 intrinsic running capacity that simultaneously associates with poor or good metabolic health  
312 (21), we report evidence for divergent skeletal muscle miRNA expression profiles .  
313 Specifically, 15 miRNAs with predicted mRNA targets involved in mitochondrial  
314 dysfunction and substrate oxidation were differentially expressed between HCR and LCR  
315 rats. Moreover, we show the abundance of predicted protein targets CS and VDAC1 were  
316 altered between phenotypes in accordance with miRNA expression profile. These findings  
317 suggest a regulatory role for specific skeletal muscle miRNAs of target proteins central to  
318 mitochondrial content and function.

319

320 MicroRNAs are critical regulators of skeletal muscle metabolism via the negative regulation  
321 of proteins involved in mitochondrial function and energy substrate oxidation (42). We  
322 therefore investigated the molecular events that may influence the diverse transcriptional  
323 differences in mitochondrial function and substrate handling previously reported between  
324 LCR and HCR rats (25, 32, 34, 39). Of the 84 most abundant miRNAs present in rats, there  
325 was a total of 5672 predicted protein/mRNA targets (2964 in skeletal muscle) arising from

326 the 15 differentially expressed miRNAs measured by IPA's microRNA Target Filter,  
327 demonstrating the potentially widespread role for miRNAs in determining the differential  
328 between HCR and LCR intrinsic phenotypes. Eleven of these differentially expressed  
329 miRNAs showed predicted protein targets implicated in mitochondrial dysfunction as  
330 identified by IPA. Numerous studies have attributed the impaired metabolic phenotype of  
331 LCR rats partly to a decrease in the abundance of skeletal muscle proteins critical to  
332 mitochondrial function (15, 34, 38). Therefore, we hypothesised that miRNAs may be a  
333 contributing regulatory mechanism to the divergent mitochondrial features and metabolic  
334 phenotypes previously characterized between HCR and LCR rats.

335

336 The first novel finding of our work was the greater miR-19a-3p expression in LCR compared  
337 to HCR rats (~63% percent change; Figure 1), which has predicted targets involved in  
338 mitochondrial dysfunction and the TCA cycle. We quantified the abundance of these  
339 predicted targets (Beta-site APP cleaving enzyme 1 and Citrate Synthase) to investigate  
340 putative interactions, finding a ~57% decrease in citrate synthase (CS) protein expression in  
341 TA from LCR rats compared to HCR rats (Figure 3). This decrease in protein expression was  
342 also supported by a reduction in citrate synthase activity (Figure 5). This is in agreement with  
343 previous reports of greater CS abundance and activity in the *m. gastrocnemius*, *m. soleus* and  
344 *m. extensor digitorum longus* of HCR rats relative to LCR rats (12, 15, 30, 33, 34, 38, 40).  
345 CS is a rate limiting enzyme of the TCA cycle located in the mitochondrial matrix and is  
346 often used as a surrogate measure for skeletal muscle mitochondrial content (22). Attenuated  
347 CS activity and abundance has been reported in the skeletal muscle of type 2 diabetic and  
348 obese individuals (18, 19, 36). Here, we report an inverse correlation between miR-19a-3p  
349 and CS expression in muscle from LCR rats, which is the first experimental evidence that  
350 miR-19a-3p may play a role in determining the mitochondrial capacity of skeletal muscle.

351

352 To confirm whether miR-19a-3p can directly bind and regulate CS transcription, C2C12  
353 myoblasts were co-transfected with a reporter plasmid containing a section of the putative rat  
354 miR-19a-3p Citrate Synthase target site, as well as the miR-19-3p mimic, an irrelevant  
355 miRNA that did not have a predicted binding site on the CS 3'UTR (miR-99b-5p) or no  
356 mimic at all. No reduction in luminescence levels was observed with miR-19a-3p, indicating  
357 that miR-19a-3p did not bind to the CS 3'UTR. CS gene expression data further supports this  
358 as no down-regulation of CS mRNA expression was observed following miR-19a-3p  
359 transfection. In contrast, overexpression of miR-19a-3p in C2C12 myoblasts decreased CS  
360 protein levels 4 h after the onset of transfection when compared to a scrambled control. This  
361 interaction may be direct and occur at the protein level to inhibit protein translation while  
362 allowing normal mRNA transcription. Alternatively, miR-19a-3p may interact with CS in  
363 area outside the 3'UTR to regulate its mRNA expression (23). Our findings therefore suggest  
364 that miR-19a-3p mediate signalling events controlling energy substrate metabolism and  
365 mitochondrial content, and reveal novel mechanistic information to the regulatory control of  
366 CS expression in skeletal muscle.

367

368 Another major finding from our study was the higher miR-7a expression in LCR rats (~35%  
369 percent change; Figure 1). miR-7a has been implicated in the development of insulin  
370 resistance through its down-regulation of insulin receptor substrate 1 expression and  
371 inhibition of insulin-stimulated Akt phosphorylation and glucose uptake (26). Considering  
372 LCR rats present impaired skeletal muscle insulin signalling and IRS1 phosphorylation  
373 relative to HCR (33), and miR-7a was more highly expressed in LCR rats, it is possible miR-  
374 7a may play a role in the attenuated insulin signalling response between these cohorts. Two  
375 protein targets of miR-7a identified by IPA in the 'Mitochondrial Dysfunction' filter were

376 VDAC1 and BACE1. VDAC1 is an outer mitochondrial membrane protein involved in the  
377 TCA cycle responsible for transporting calcium ions and metabolites including ATP across  
378 the outer mitochondrial membrane (35). VDAC1 deficient mice have been shown to display  
379 impaired glucose tolerance and exercise capacity due to impaired mitochondria-bound  
380 hexokinase activity (1). In our study, the first to compare VDAC1 protein expression between  
381 LCR and HCR rats, we observed significantly lower VDAC1 protein expression in the LCR  
382 cohort. This raises the possibility that miR-7a and VDAC1 may contribute to the divergent  
383 metabolic profiles previously established between LCR and HCR (33). Further work  
384 incorporation miR-7a over-expression analyses are required to better understand the capacity  
385 for it to regulate cellular energy production and metabolism processes.

386

387 Of the other protein targets analysed from the differentially expressed miRNAs between LCR  
388 and HCR cohorts, protein levels of Glycerol-3-Phosphate Dehydrogenase 2 (GPD2) were  
389 higher in LCR compared to HCR rats. GPD2 is a mitochondrial membrane protein centrally  
390 involved in glycolysis and was a predicted target of miR-30a. While increased GPD2  
391 abundance in LCR skeletal muscle was unexpected based on higher miR-30a expression  
392 profile in LCR compared to HCR rats, this higher abundance of GPD2 indicates a greater  
393 reliance on glycolysis for energy production compared to HCR rats. Indeed, previous work  
394 from our laboratory has demonstrated that LCR skeletal muscle is more reliant on  
395 carbohydrate than fat metabolism at rest (33). These findings suggest other signalling  
396 mechanisms or miRNAs further to those investigated here are likely to regulate GPD2 protein  
397 expression. The miR-103-3p was another miRNA that presented higher expression in the  
398 HCR cohort of the differentially expressed miRNAs. Little is known about the role and  
399 validated targets of miR-103 with this the first study to investigate its expression in rat  
400 skeletal muscle. IPA analysis identified BACE1 and CASP3 to be targets of miR-103 within



401 the mitochondrial dysfunction filter; however both of these proteins presented similar  
402 expression patterns between cohorts. Previous research has suggested a role for miR-103 in  
403 myogenic differentiation with increased miR-103 expression observed in myoblasts  
404 following differentiation (7). It is possible that potential increases in myogenic differentiation  
405 regulated by miR-103 may contribute to increased skeletal muscle oxidative capacity in HCR  
406 rats previously identified by our group (32) by promoting increased muscle mass and  
407 represents an avenue for further investigation.

408

409 While there were no other differences in the expression levels of target proteins from other  
410 miRNAs differentially expressed between LCR and HCR rats, many of these miRNAs have  
411 been shown to be implicated in metabolic disorders and the regulation of mitochondrial  
412 function and protein expression. For instance, global and skeletal muscle specific  
413 overexpression of the let-7 family (including the differentially expressed let-7i and -7e  
414 miRNAs investigated in our work) has been reported to impair glucose tolerance and induce  
415 insulin resistance (9, 44). As transgenic mouse experiments have shown that let-7 targets the  
416 insulin receptor in skeletal muscle (44), it is possible the increased expression of let-7i and -  
417 7e in LCR rats may contribute to the previously reported impaired insulin signaling responses  
418 in LCR rats (24, 25, 32). An important limitation of our results is that analysis was only  
419 confined to the tibialis anterior. Differences in type IIb and type IIx fibre types exist between  
420 LCR and HCR cohorts within the Tibialis Anterior (Seifort), thus we cannot rule out that  
421 differences in miRNA expression or citrate synthase activity may be influenced by these  
422 discrepancies in fibre type. Moreover, it is also plausible that other tissues (i.e.: heart) may  
423 impact miRNA expression differently between LCR and HCR compared to our observed  
424 results in the tibialis anterior.

425

426 In conclusion, we demonstrate highly divergent skeletal muscle miRNA expression profiles  
427 between LCR and HCR rats, targeting multiple predicted protein/mRNA targets involved in  
428 mitochondrial function and substrate metabolism. These findings suggest that altered miRNA  
429 expression may mediate some of the metabolic features intrinsic to HCR and LCR rats and  
430 demonstrate the potential for miRNAs to regulate metabolic function and provide insight into  
431 the gene-regulatory mechanisms modulating intrinsic running capacity and its link to  
432 metabolic health. Further work investigating the effect of exercise in the LCR/HCR model  
433 would provide additional information regarding the regulation of miRNA expression in  
434 skeletal muscle. Future research is also warranted to identify and validate specific gene  
435 targets of miRNAs differentially expressed between HCR and LCR phenotypes and elucidate  
436 their potential regulatory role in metabolic health. Such interactions need to be confirmed in  
437 human skeletal muscle in order to become potential novel targets for mitochondrial-based  
438 therapies for the treatment of metabolic-related conditions aimed at increasing energy  
439 expenditure or enhancing substrate oxidation.

440

#### 441 **Acknowledgements**

442 This study was funded by a grant to JAH from the Novo Nordisk Foundation  
443 (NNF14OC0011493). Severine Lamon was supported by a Discovery Early Career Research  
444 Award (DECRA) from the Australian Research Council (ARC) (DE150100538). The LCR-  
445 HCR rat model system was funded by the Office of Research Infrastructure Programs grant  
446 P40OD021331 (to LGK and SLB) from the National Institutes of Health. We acknowledge  
447 the expert care of the rat colony provided by Lori Heckenkamp and Shelby Raupp. Contact  
448 LGK [lgkoch@umich.edu](mailto:lgkoch@umich.edu) or SLB [brittons@umich.edu](mailto:brittons@umich.edu) for information on the LCR and HCR  
449 rats: these rat models are maintained as an international resource with support from the  
450 Department of Anesthesiology at the University of Michigan, Ann Arbor, Michigan

451 **Table 1.** Relative expression of the 65 miRNAs which were not significantly different ( $P <$   
452 0.05) between TA of HCR and LCR rats as determined by qRT-PCR ( $n = 9$ ). Values are  
453 means  $\pm$  SD.

454 **Figure 1.** Relative expression of miRNAs differentially expressed ( $*P < 0.05$ ) in the TA of  
455 generation 27 HCR and LCR rats as determined by qRT-PCR ( $n = 9$ ). Values are means  $\pm$   
456 SD.

457 **Figure 2.** Pathway analysis of the 11 differentially expressed miRNAs between HCR and  
458 LCR rats and their 19 protein/mRNA targets within the ‘Mitochondrial Dysfunction’ and  
459 ‘TCA Cycle II (Eukaryotic)’ pathways in skeletal muscle as predicted by the microRNA  
460 Target Filter of Qiagen’s Ingenuity Pathway Analysis. Relationships are either ‘highly  
461 predicted’ by algorithms or ‘experimentally observed’ in previous literature.

462

463 **Figure 3.** A) ATPAF1 (target of miR-26a, miR-28-5p, let-7i-5p and let-7e-5p), B) BACE1  
464 (target of miR-103-3p, miR-374-5p, miR-7a-5p and miR-19a-3p-3p), C) CASP3 (target of  
465 miR-103-rp, let-7e-5p and let-7i-5p), D) CS (target of miR-19a-3p-3p), E) GPD2 (target of  
466 miR-30a-5p), F) LRRK2 (target of miR-19a-3p-3p and miR-181a-5p), G) MAP2K4 (target of  
467 miR-24-3p and miR-374-5p) and H) VDAC1 (target of miR-7a-5p) total protein content in  
468 the TA of HCR and LCR rats ( $n = 9$ ). Values are arbitrary units expressed relative to Stain-  
469 Free total protein loading. (\*) Significantly different ( $P < 0.05$ ) between LCR and HCR  
470 cohorts. Values are means  $\pm$  SD.

471

472 **Figure 4.** Correlation analysis between miR-19a-3p and its predicted protein target CS in the  
473 TA of LCR rats ( $n=9$ ).

474

475 **Figure 5.** CS activity in the TA of HCR and LCR rats ( $n = 10$ ). Values are means  $\pm$  SD (\*P <  
476 0.05).

477 **Figure 6.** A) MicroRNA expression levels of miR-19a-3p normalized to SnoRNA202 after  
478 transfection in C2C12 cells; B) mRNA and C) protein expression of the miR-19a-3p  
479 predicted target CS following transfection (\*P < 0.05).

480  
481 **Figure 7.** Representative stain-free image of total protein loading for A) TA of HCR and  
482 LCR rats; and B) C2C12 cells following miR-19-3p transfection.

483

484

485

486

487

488

489

490

491

492

493

494

495

496 **References**

- 497 1. **Anflous-Pharayra K, Cai Z-J, and Craigen WJ.** VDAC1 serves as a mitochondrial binding site  
498 for hexokinase in oxidative muscles. *Biochimica et Biophysica Acta (BBA)-Bioenergetics* 1767: 136-  
499 142, 2007.
- 500 2. **Bartel DP.** MicroRNAs: genomics, biogenesis, mechanism, and function. *cell* 116: 281-297,  
501 2004.
- 502 3. **Camera DM, Ong JN, Coffey VG, and Hawley JA.** Selective Modulation of MicroRNA  
503 Expression with Protein Ingestion Following Concurrent Resistance and Endurance Exercise in  
504 Human Skeletal Muscle. *Frontiers in physiology* 7: 87, 2016.
- 505 4. **Christian P, and Su Q.** MicroRNA regulation of mitochondrial and ER stress signaling  
506 pathways: implications for lipoprotein metabolism in metabolic syndrome. *Am J Physiol Endocrinol*  
507 *Metab* 307: E729-737, 2014.
- 508 5. **Davidson PK, Gallagher IJ, Hartman JW, Tarnopolsky MA, Dela F, Helge JW, Timmons JA,**  
509 **and Phillips SM.** High responders to resistance exercise training demonstrate differential regulation  
510 of skeletal muscle microRNA expression. *Journal of applied physiology* 110: 309-317, 2011.
- 511 6. **Dawes M, Kochan KJ, Riggs PK, and Lightfoot JT.** Differential miRNA expression in inherently  
512 high-and low-active inbred mice. *Physiological reports* 3: e12469, 2015.
- 513 7. **Dmitriev P, Barat A, Polesskaya A, O'Connell MJ, Robert T, Dessen P, Walsh TA, Lazar V,**  
514 **Turki A, Carnac G, Laoudj-Chenivesse D, Lipinski M, and Vassetzky YS.** Simultaneous miRNA and  
515 mRNA transcriptome profiling of human myoblasts reveals a novel set of myogenic differentiation-  
516 associated miRNAs and their target genes. *BMC Genomics* 14: 265, 2013.
- 517 8. **Duarte FV, Palmeira CM, and Rolo AP.** The Role of microRNAs in Mitochondria: Small  
518 Players Acting Wide. *Genes (Basel)* 5: 865-886, 2014.
- 519 9. **Frost RJ, and Olson EN.** Control of glucose homeostasis and insulin sensitivity by the Let-7  
520 family of microRNAs. *Proceedings of the National Academy of Sciences* 108: 21075-21080, 2011.
- 521 10. **Geeleher P, Huang SR, Gamazon ER, Golden A, and Seoighe C.** The regulatory effect of  
522 miRNAs is a heritable genetic trait in humans. *BMC Genomics* 13: 383, 2012.
- 523 11. **Geiger J, and Dalgaard LT.** Interplay of mitochondrial metabolism and microRNAs. *Cell Mol*  
524 *Life Sci* 2016.
- 525 12. **Gonzalez NC, Howlett RA, Henderson KK, Koch LG, Britton SL, Wagner HE, Favret F, and**  
526 **Wagner PD.** Systemic oxygen transport in rats artificially selected for running endurance. *Respiratory*  
527 *physiology & neurobiology* 151: 141-150, 2006.
- 528 13. **Guller I, and Russell AP.** MicroRNAs in skeletal muscle: their role and regulation in  
529 development, disease and function. *The Journal of physiology* 588: 4075-4087, 2010.
- 530 14. **Gürtler A, Kunz N, Gomolka M, Hornhardt S, Friedl AA, McDonald K, Kohn JE, and Posch A.**  
531 Stain-Free technology as a normalization tool in Western blot analysis. *Analytical biochemistry* 433:  
532 105-111, 2013.
- 533 15. **Howlett RA, Gonzalez NC, Wagner HE, Fu Z, Britton SL, Koch LG, and Wagner PD.** Selected  
534 contribution: skeletal muscle capillarity and enzyme activity in rats selectively bred for running  
535 endurance. *Journal of applied physiology* 94: 1682-1688, 2003.
- 536 16. **Howlett RA, Gonzalez NC, Wagner HE, Fu Z, Britton SL, Koch LG, and Wagner PD.** Selected  
537 contribution: skeletal muscle capillarity and enzyme activity in rats selectively bred for running  
538 endurance. *J Appl Physiol (1985)* 94: 1682-1688, 2003.
- 539 17. **Kelley DE.** Skeletal muscle fat oxidation: timing and flexibility are everything. *Journal of*  
540 *Clinical Investigation* 115: 1699, 2005.
- 541 18. **Kelley DE, He J, Menshikova EV, and Ritov VB.** Dysfunction of mitochondria in human  
542 skeletal muscle in type 2 diabetes. *Diabetes* 51: 2944-2950, 2002.
- 543 19. **Kim J-Y, Hickner RC, Cortright RL, Dohm GL, and Houmard JA.** Lipid oxidation is reduced in  
544 obese human skeletal muscle. *American Journal of Physiology-Endocrinology And Metabolism* 279:  
545 E1039-E1044, 2000.

- 546 20. **Koch LG, and Britton SL.** Artificial selection for intrinsic aerobic endurance running capacity  
547 in rats. *Physiological genomics* 5: 45-52, 2001.
- 548 21. **Koch LG, Britton SL, and Wisloff U.** A rat model system to study complex disease risks,  
549 fitness, aging, and longevity. *Trends Cardiovasc Med* 22: 29-34, 2012.
- 550 22. **Larsen S, Nielsen J, Hansen CN, Nielsen LB, Wibrand F, Stride N, Schroder HD, Boushel R,**  
551 **Helge JW, Dela F, and Hey-Mogensen M.** Biomarkers of mitochondrial content in skeletal muscle of  
552 healthy young human subjects. *The Journal of physiology* 590: 3349-3360, 2012.
- 553 23. **Lee I, Ajay SS, Yook JI, Kim HS, Hong SH, Kim NH, Dhanasekaran SM, Chinnaiyan AM, and**  
554 **Athey BD.** New class of microRNA targets containing simultaneous 5'-UTR and 3'-UTR interaction  
555 sites. *Genome Res* 19: 1175-1183, 2009.
- 556 24. **Lessard SJ, Rivas DA, Chen ZP, van Denderen BJ, Watt MJ, Koch LG, Britton SL, Kemp BE,**  
557 **and Hawley JA.** Impaired skeletal muscle beta-adrenergic activation and lipolysis are associated with  
558 whole-body insulin resistance in rats bred for low intrinsic exercise capacity. *Endocrinology* 150:  
559 4883-4891, 2009.
- 560 25. **Lessard SJ, Rivas DA, Stephenson EJ, Yaspelkis BB, 3rd, Koch LG, Britton SL, and Hawley JA.**  
561 Exercise training reverses impaired skeletal muscle metabolism induced by artificial selection for low  
562 aerobic capacity. *Am J Physiol Regul Integr Comp Physiol* 300: R175-182, 2011.
- 563 26. **Li Z-Y, Na H-M, Peng G, Pu J, and Liu P.** Alteration of microRNA expression correlates to fatty  
564 acid-mediated insulin resistance in mouse myoblasts. *Molecular BioSystems* 7: 871-877, 2011.
- 565 27. **Lima TI, Araujo HN, Menezes ES, Sponton CH, Araujo MB, Bomfim LH, Queiroz AL, Passos**  
566 **MA, TA ES, Hirabara SM, Martins AR, Sampaio HC, Rodrigues A, Curi R, Carneiro EM, Boschero AC,**  
567 **and Silveira LR.** Role of microRNAs on the Regulation of Mitochondrial Biogenesis and Insulin  
568 Signaling in Skeletal Muscle. *J Cell Physiol* 2016.
- 569 28. **Livak KJ, and Schmittgen TD.** Analysis of relative gene expression data using real-time  
570 quantitative PCR and the 2<sup>-</sup>(Delta Delta C(T)) Method. *Methods* 25: 402-408, 2001.
- 571 29. **Naples SP, Borengasser SJ, Rector RS, Uptergrove GM, Morris EM, Mikus CR, Koch LG,**  
572 **Britton SL, Ibdah JA, and Thyfault JP.** Skeletal muscle mitochondrial and metabolic responses to a  
573 high-fat diet in female rats bred for high and low aerobic capacity. *Applied Physiology, Nutrition, and*  
574 *Metabolism* 35: 151-162, 2010.
- 575 30. **Noland RC, Thyfault JP, Henes ST, Whitfield BR, Woodlief TL, Evans JR, Lust JA, Britton SL,**  
576 **Koch LG, and Dudek RW.** Artificial selection for high-capacity endurance running is protective  
577 against high-fat diet-induced insulin resistance. *American Journal of Physiology-Endocrinology and*  
578 *Metabolism* 293: E31-E41, 2007.
- 579 31. **Ren YY, Overmyer KA, Qi NR, Treutelaar MK, Heckenkamp L, Kalahar M, Koch LG, Britton**  
580 **SL, Burant CF, and Li JZ.** Genetic analysis of a rat model of aerobic capacity and metabolic fitness.  
581 *PLoS One* 8: e77588, 2013.
- 582 32. **Rivas DA, Lessard SJ, Saito M, Friedhuber AM, Koch LG, Britton SL, Yaspelkis BB, 3rd, and**  
583 **Hawley JA.** Low intrinsic running capacity is associated with reduced skeletal muscle substrate  
584 oxidation and lower mitochondrial content in white skeletal muscle. *Am J Physiol Regul Integr Comp*  
585 *Physiol* 300: R835-843, 2011.
- 586 33. **Rivas DA, Lessard SJ, Saito M, Friedhuber AM, Koch LG, Britton SL, Yaspelkis BB, and**  
587 **Hawley JA.** Low intrinsic running capacity is associated with reduced skeletal muscle substrate  
588 oxidation and lower mitochondrial content in white skeletal muscle. *American Journal of Physiology-*  
589 *Regulatory, Integrative and Comparative Physiology* 300: R835-R843, 2011.
- 590 34. **Seifert EL, Bastianelli M, Aguer C, Moffat C, Estey C, Koch LG, Britton SL, and Harper ME.**  
591 Intrinsic aerobic capacity correlates with greater inherent mitochondrial oxidative and H<sub>2</sub>O<sub>2</sub>  
592 emission capacities without major shifts in myosin heavy chain isoform. *J Appl Physiol (1985)* 113:  
593 1624-1634, 2012.
- 594 35. **Shoshan-Barmatz V, De Pinto V, Zweckstetter M, Raviv Z, Keinan N, and Arbel N.** VDAC, a  
595 multi-functional mitochondrial protein regulating cell life and death. *Molecular aspects of medicine*  
596 31: 227-285, 2010.

- 597 36. **SIMONEAU J-A, VEERKAMP JH, TURCOTTE LP, and KELLEY DE.** Markers of capacity to utilize  
598 fatty acids in human skeletal muscle: relation to insulin resistance and obesity and effects of weight  
599 loss. *The FASEB Journal* 13: 2051-2060, 1999.
- 600 37. **Srere P.** [1] Citrate synthase:[EC 4.1. 3.7. Citrate oxaloacetate-lyase (CoA-acetylating)].  
601 *Methods in enzymology* 13: 3-11, 1969.
- 602 38. **Stephenson EJ, Stepto NK, Koch LG, Britton SL, and Hawley JA.** Divergent skeletal muscle  
603 respiratory capacities in rats artificially selected for high and low running ability: a role for Nor1?  
604 *Journal of applied physiology* 113: 1403-1412, 2012.
- 605 39. **Stephenson EJ, Stepto NK, Koch LG, Britton SL, and Hawley JA.** Divergent skeletal muscle  
606 respiratory capacities in rats artificially selected for high and low running ability: a role for Nor1? *J*  
607 *Appl Physiol (1985)* 113: 1403-1412, 2012.
- 608 40. **Tweedie C, Romestaing C, Burelle Y, Safdar A, Tarnopolsky MA, Seadon S, Britton SL, Koch**  
609 **LG, and Hepple RT.** Lower oxidative DNA damage despite greater ROS production in muscles from  
610 rats selectively bred for high running capacity. *American Journal of Physiology-Regulatory,*  
611 *Integrative and Comparative Physiology* 300: R544-R553, 2011.
- 612 41. **Wisloff U, Najjar SM, Ellingsen O, Haram PM, Swoap S, Al-Share Q, Fernstrom M, Rezaei K,**  
613 **Lee SJ, Koch LG, and Britton SL.** Cardiovascular risk factors emerge after artificial selection for low  
614 aerobic capacity. *Science (New York, NY)* 307: 418-420, 2005.
- 615 42. **Zacharewicz E, Lamon S, and Russell AP.** MicroRNAs in skeletal muscle and their regulation  
616 with exercise, ageing, and disease. *Frontiers in physiology* 4: 266, 2013.
- 617 43. **Zhang Y, Yang L, Gao Y-F, Fan Z-M, Cai X-Y, Liu M-Y, Guo X-R, Gao C-L, and Xia Z-K.**  
618 MicroRNA-106b induces mitochondrial dysfunction and insulin resistance in C2C12 myotubes by  
619 targeting mitofusin-2. *Molecular and cellular endocrinology* 381: 230-240, 2013.
- 620 44. **Zhu H, Shyh-Chang N, Segrè AV, Shinoda G, Shah SP, Einhorn WS, Takeuchi A, Engreitz JM,**  
621 **Hagan JP, and Kharas MG.** The Lin28/let-7 axis regulates glucose metabolism. *Cell* 147: 81-94, 2011.